Antibiotic treatment of <i>mycoplasma pneumoniae</i> infections

Gendrel, D.

doi:10.1002/ppul.1950230824

Cited by 11 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The age at which one should begin to strongly consider M. pneumoniae as the cause of CAP is not well defined. M. pneumoniae is increasingly being diagnosed serologically as a cause of LRTI in young children [15,17,18,[118][119][120][121][122]. Testing may not be necessary in children with a low likelihood of M. pneumoniae infection (eg, younger children with symptoms more compatible with a primary viral upper respiratory tract infection), in whom the positive predictive value of a positive test may only be modest (ie, false-positive results will occur).…”

Section: Testing For Atypical Bacteriamentioning

confidence: 99%

The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America

Bradley

Byington

Shah

et al. 2011

Clinical Infectious Diseases

1,333

1,549

View full text Add to dashboard Cite

Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine, infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings. Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted.

show abstract

Section: Testing For Atypical Bacteriamentioning

confidence: 99%

The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America

Bradley

Byington

Shah

et al. 2011

Clinical Infectious Diseases

1,333

1,549

View full text Add to dashboard Cite

show abstract

“…pneumoniae causes up to 40% or more of cases of community-acquired pneumonias and as many as 18% of cases requiring hospitalization in children (5,47,137,156,180,182,199,273,357,403,446). Older studies relying upon serology and culture reported M. pneumoniae pneumonia to be somewhat uncommon in children aged less than 5 years and greatest among school-aged children 5 to 15 years of age, with a decline after adolescence and on into adulthood (5,(143)(144)(145).…”

Section: Demographics and Spectrum Of Diseasementioning

confidence: 99%

Mycoplasma pneumoniaeand Its Role as a Human Pathogen

2004

View full text Add to dashboard Cite

Mycoplasma pneumoniae is a unique bacterium that does not always receive the attention it merits considering the number of illnesses it causes and the degree of morbidity associated with it in both children and adults. Serious infections requiring hospitalization, while rare, occur in both adults and children and may involve multiple organ systems. The severity of disease appears to be related to the degree to which the host immune response reacts to the infection. Extrapulmonary complications involving all of the major organ systems can occur in association with M. pneumoniae infection as a result of direct invasion and/or autoimmune response. The extrapulmonary manifestations are sometimes of greater severity and clinical importance than the primary respiratory infection. Evidence for this organism's contributory role in chronic lung conditions such as asthma is accumulating. Effective management of M. pneumoniae infections can usually be achieved with macrolides, tetracyclines, or fluoroquinolones. As more is learned about the pathogenesis and immune response elicited by M. pneumoniae, improvement in methods for diagnosis and prevention of disease due to this organism may occur

show abstract

“…In the last few decades, M. pneumoniae respiratory infection has drawn increasing attention for its association with reactive airway disease and asthma (22)(23)(24). Clinical studies have shown that therapy with macrolides or tetracyclines, which are considered the drugs of choice for M. pneumoniae (11), is able to reduce the morbidity of pneumonia, shorten the duration of symptoms, and decrease the recurrence of wheezing (5,7,8,12,25,26). However, even though treatment with macrolide, ketolide, and peptide deformylase inhibitor antimicrobials significantly improves pulmonary inflammation in animal M. pneumoniae pneumonia investigations, M. pneumoniae is not eradicated from the lungs in these in vivo investigations (10,15,31,32).…”

mentioning

confidence: 99%

Tigecycline Therapy Significantly Reduces the Concentrations of Inflammatory Pulmonary Cytokines and Chemokines in a Murine Model of Mycoplasma pneumoniae Pneumonia

Salvatore¹,

Techasaensiri²,

Tagliabue

et al. 2009

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Antimicrobials have been used successfully for the treatment of many infectious diseases; however, the continuous increase in resistance among many bacteria in the community, as well as in the hospital setting, has led to research for new classes of antibiotics with a broader range of activity against pathogenic microorganisms (2,6,17,18). Tigecycline is a novel antibiotic, a 9-t-butylglycylamido derivative of minocyline, which inhibits protein synthesis in the presence of tetracycline-resistant, tet(M)-protected ribosomes (30); it belongs to a new semisynthetic class of antimicrobials named glycylcyclines (37). It has been shown to have activity against a wide range of microorganisms, both gram-positive and gram-negative bacteria, as well as anaerobes (16,29,39). Moreover tigecycline has activity in vitro against rapidly growing mycobacteria, such as Mycobacterium chelonae and Mycobacterium fortuitum, as well as atypical respiratory pathogens, such as Mycoplasma pneumoniae (20,21,41). In animal pneumonia models, tigecycline has been shown to have effective activity against Legionella pneumophila, Pseudomonas aeruginosa, and Streptococcus pneumoniae pulmonary infections (33).M. pneumoniae is an "atypical" bacterium that lacks a cell wall and plays an important role in acute lower respiratory tract infections in children and adults; approximately 20 to 30% of community-acquired pneumonia in the general population is due to M. pneumoniae (1,3,27,42). In the last few decades, M. pneumoniae respiratory infection has drawn increasing attention for its association with reactive airway disease and asthma (22)(23)(24). Clinical studies have shown that therapy with macrolides or tetracyclines, which are considered the drugs of choice for M. pneumoniae (11), is able to reduce the morbidity of pneumonia, shorten the duration of symptoms, and decrease the recurrence of wheezing (5,7,8,12,25,26). However, even though treatment with macrolide, ketolide, and peptide deformylase inhibitor antimicrobials significantly improves pulmonary inflammation in animal M. pneumoniae pneumonia investigations, M. pneumoniae is not eradicated from the lungs in these in vivo investigations (10,15,31,32). Of note, in these experimental investigations examining the effects of antimicrobials for M. pneumoniae pneumonia, a disassociation is often found between the microbiologic response and the significant improvement observed in other markers of disease severity. While tigecycline demonstrates in vitro activity against M. pneumoniae, tigecycline therapy in vivo for M. pneumoniae pneumonia has not been evaluated. In the present study, we investigate the effect of tigecycline on microbiologic, histologic, and immunologic (pulmonary cytokine and chemokine) parameters in our established murine model of M. pneumoniae pneumonia (9, 10, 14, 15).

show abstract

Antibiotic treatment of mycoplasma pneumoniae infections

Cited by 11 publications

References 0 publications

The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America

The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America

Mycoplasma pneumoniaeand Its Role as a Human Pathogen

Tigecycline Therapy Significantly Reduces the Concentrations of Inflammatory Pulmonary Cytokines and Chemokines in a Murine Model of Mycoplasma pneumoniae Pneumonia

Contact Info

Product

Resources

About